Nos publications
Ethanol resistant extended release matrix tablets with Compritol® 888 ATO
AAPS Annual Meeting and Exposition – San Diego (USA) - nov 2014
Effect of Tablet Structure on Controlled Release from Supersaturating Solid Dispersions Containing Glyceryl Behenate.
Mol. Pharmaceutics, 2015, 12 (1), pp 120–126 DOI: 10.1021/mp500480y - oct 2014
Solid lipid excipients — Matrix agents for sustained drug delivery
Journal of Controlled Release Volume 188, Pages 18–30 - aou 2014
This review article focuses on the utility of lipid excipients in solid sustained drug delivery systems with emphasis on the efficiency and robustness of these systems with respect to: (i) the choice of the manufacturing process and impact on drug release, (ii) the fundamental drug release mechanisms, (iii) resistance of the drug formulation under physiological conditions and (iv) long-term stability. Understanding the functionality of these versatile excipients in formulation is elementary for the development of highly robust lipid-based sustained release medicines
Estimating in vivo drug release from a new theophylline Compritol® 888 ATO matrix formulation using appropriate biorelevant test methods
CRS Annual Meeting – Chicago (USA) - jui 2014
Streamlining the design of sustained release matrix tablets using mathematical modeling for drug release optimization
CRS Annual Meeting – Chicago (USA) - jui 2014
Smart strategies for sustained release matrix tablets: Compritol® 888 ATO
OutsourcingPharma - mai 2014
This white paper gives an overview of how Compritol® 888 ATO provides clinically relevant sustained drug release profiles along with biopharmaceutical, formulation and manufacturing advantages.